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Abstract
Human immunodeficiency virus type 1 (HIV-1) transmission and infection occur mainly via the 
mucosal surfaces. The commensal bacteria residing in these surfaces can potentially be employed 
as a vehicle for delivering inhibitors to prevent HIV-1 infection. In this study, we have employed a 
bacteria-based strategy to display a broadly neutralizing antibody VRC01, which could potentially 
be used to prevent HIV-1 infection. The VRC01 antibody mimics CD4-binding to gp120 and has 
broadly neutralization activities against HIV-1. We have designed a construct that can express the 
fusion peptide of the scFv-VRC01 antibody together with the autotransporter β-barrel domain of 
IgAP gene from Neisseria gonorrhoeae, which enabled surface display of the antibody molecule. 
Our results indicate that the scFv-VRC01 antibody molecule was displayed on the surface of the 
bacteria as demonstrated by flow cytometry and immunofluorescence microscopy. The engineered 
bacteria can capture HIV-1 particles via surface-binding and inhibit HIV-1 infection in cell 
culture.
Introduction
The Acquired Immunodeficiency Syndrome (AIDS) pandemic caused by the human 
immunodeficiency virus type 1 (HIV-1) has been ongoing for over three decades (Barre-
Sinoussi et al., 1983; Schupbach et al., 1984). It is estimated that 39 million people have 
already died of AIDS-related diseases; 35 million people are living with HIV-1, and 2.1 
million people are newly infected each year (UNAIDS, 2014). In spite of the recent 
optimism regarding a functional cure for HIV-1, there are still substantial obstacles for 
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achieving a sterilizing cure with the current available treatment regimens. Therefore, 
preventing new infection is still the priority for curbing the AIDS epidemic. So far, much 
effort has been dedicated towards the development of an effective AIDS vaccine, but none 
has yet been successful (Burton et al., 2012; Johnston and Fauci, 2011; Lifson and 
Haigwood, 2012; O’Connell et al., 2012; Xiang, 2013). Therefore, other alternative 
prevention approaches are needed in order to curtail HIV-1 transmission and infection.
There are several reports on a new prevention approach using gram-positive bacteria, such 
as lactobacilli, for surface display of CD4 (2-domains) (Liu et al., 2008), HIV-1 entry 
inhibitor cyanovirin-N (CV-N) (Lagenaur et al., 2011; Liu et al., 2006; Yamamoto et al., 
2013), or for secretion of a CCR5 antagonist RANTES (Vangelista et al., 2010) and HIV-1 
fusion peptide inhibitors (Pusch et al., 2006) to prevent HIV-1 infection. These approaches 
involve the use of bacteria to synthesize anti-HIV-1 inhibitors that can be secreted or 
displayed on the cell surface so that the inhibitors can bind to the virus and prevent 
infection. Since these commensal bacteria inhabit the mucosal sites which are the port of 
entry for HIV-1, these protein-based inhibitors can be produced by the bacteria which can be 
maintained as part of the normal mucosal bacterial flora, this approach could thus be 
employed as a potential strategy to prevent HIV-1 infection.
Gram-negative bacteria have also been used for a number of therapeutic applications 
including gene delivery into the gut (Castagliuolo et al., 2005). Succesful attempts include 
surface display of lipase (Lee et al., 2013), antimicrobial peptides (Shin et al., 2013), p-
glucuronidase (Cheng et al., 2013) and also for the secretion of single-chain or Fab antibody 
fragments (Cheung et al., 1992; Fallecker et al., 2013; Fernandez et al., 2000). However, 
very few studies have been reported in the use of gram-negative bacteria as potential agents 
for the delivery (Abdel-Mohsen et al., 2013) of anti-HIV regimens. So far only one study 
has been reported in which Escherichia coli Nissle 1917 was used to secrete an anti-HIV-1 
fusion peptide inhibitor to target gp41 glycoprotein of the virus. The fusion peptides from 
bacterial secretion can inhibit viral infection in cell culture experiments, and bacterial 
colonization in mice can last for weeks, or in some cases even months, however, the viral 
challenge experiment in vivo has not yet been carried out as the mice cannot directly be used 
for HIV-1 infection (Rao et al., 2005). Surface display of anti-HIV-1 inhibitors on gram-
negative bacteria is another approach in this commensal bacterial strategy, but it has not yet 
been tested. For surface display, the bacterial transporter genes must be used to translocate 
the molecules of interest onto the cell surface (Castagliuolo et al., 2005; Fairman et al., 
2011; Jose et al., 2012). Among the known transporters, the autotranspoter (AT) is one of 
the most studied, and its structure and translocating mechanisms have been reported recently 
(Benz and Schmidt, 2011; Ieva and Bernstein, 2009; Rutherford and Mourez, 2006; van den 
Berg, 2010). More importantly, these autotransporters are shown to be able to translocate 
single-chain antibody molecules onto the bacterial surface (Pyo et al., 2009; Veiga et al., 
1999, 2003).
In this report, we have used the gram-negative bacteria for surface display of anti-HIV-1 
antibody molecules. The autotransporter, an immunoglobulin A (IgA) protease gene (IgAP) 
of Neisseria gonorrhoeae, was used because its C-terminal domain has been shown to 
efficiently translocate the passenger domain at its N-terminal (Dautin and Bernstein, 2007; 
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Pohlner et al., 1987). We therefore employed this gram-negative bacterial autotransporter 
for surface display of a potent broadly neutralizing antibody (VRC01) against HIV-1 
infection. VRC01 is a potent neutralizing antibody isolated from an HIV-1 patient, which 
can neutralize about 90% of HIV-1 isolates tested (Wu et al., 2010). VRC01 binds to the 
CD4-binding site (CD4-BS) and can mimic CD4-binding to gp120 (Zhou et al., 2010). We 
have generated the single-chain variable fragment (scFv) of VRC01 antibody (scFv-VRC01) 
and displayed it on the surface of E. coli to test its ability to inhibit HIV-1 infection.
Results
Design of the scFv-VRC01 surface-display constructs
The scFv-VRC01 was designed using a two-step approach. The first was the designing of 
the single-chain (scFv) VRC01 antibody domain for expression. The VRC01 antibody gene 
was used to generate the single-chain antibody (scFv). A linker (-GGGGSGGGGSGGGGS-) 
was used to link the heavy chain (VH) and light chain (VL) gene fragments. Two E-tags 
were inserted into the recombinant gene; one was located between the β-barrel domain and 
the single-chain antibody, another was added to the N-terminus of the single-chain antibody 
(Fig. 1A). The resulting recombinant protein would display the His-tag at the C-terminus 
when expressed in the pET22b vector, and will be 257 amino acids in length with an 
expected molecular weight of about 27kDa. The designed peptide was codon-optimized and 
synthesized for the E. coli expression system. The second step was to link scFv-VRC01 
fragment to the translocator β-barrel domain (C-IgAP) from bacterial (N. gonorrhoeae) 
autotransporter (434aa), which will then generate a fusion protein (scFv-VRC01-β-barrel 
domain (C-IgAP)) of about 75kDa. The proposed structural model of the fusion recombinant 
protein molecule is shown in Fig. 1B. The scFv-VRC01 fusion upon expression is then 
expected to be displayed on the surface of the bacterial cell and bind to gp120 on the surface 
of the HIV-1 virion to inhibit viral infection.
Expression of scFv-VRC01 antibody in E. coli
The synthesized single-chain VRC01 antibody (scFv-VRC01) gene was first cloned into the 
pET28b expression vector to test for expression of the scFv-VRC01 protein with the 
predicted molecular weight of about 27 kDa. As shown in Fig. 2A, a band of 27 kDa could 
be detected in total bacterial lysates upon induction by IPTG, but was absent in both un-
induced lysates or in the supernatant of induced samples. This suggests that the single-chain 
VRC01 antibody protein molecule could be expressed in E. coli, and found mostly in the 
insoluble fractions of the bacterial lysates. The recombinant protein was then further purified 
using the Ni-NTA column and the presence of the protein was confirmed by western blot 
analysis using anti-His-tag antibody. An example of the blot is shown in Fig. 2B, confirming 
that most of the expressed protein could be found in the insoluble fraction of the bacterial 
lysate.
We then further characterized the expressed single-chain antibody VRC01 by determining 
whether it could be refolded into a native conformation, and Far-Western blotting was used 
to analyze whether it could bind gp120. This was carried out using anti-gp120 antibody to 
detect gp120 that was captured by the refolded scFv-VRC01, and the result is shown in Fig. 
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2D. The gp120 molecule was found to be bound by the refolded scFv-VRC01 on the 
membrane, resulting in the presence of a 27 kDa band which corresponds with expected size 
of the scFv-VRC01 antibody molecule and with the size of purified scFV-VRC01 shown by 
Western blot analysis using anti-His-tag antibody (Fig. 2C). Our results thus confirmed that 
the detected 27kDa recombinant protein was indeed scFv-VRC01 and when refolded, could 
bind gp120.
Inhibition of HIV-1 by the scFv-VRC01 antibody
Since the recombinant scFv-VRC01 can bind gp120 as determined by Far-Western blotting 
analysis, this suggested that the refolded SCFV-VRC01 can possibly bind and neutralize 
HIV-1. We then tested whether the expressed single-chain antibody VRC01 had neutralizing 
activity for different HIV-1 subtype strains. We tested the activities of SCFv-VRC01 against 
two different HIV-1 subtypes, subtype B (YU2) and subtype C (1084i), and the results are 
shown in Fig. 3A. The sc-Fv-VRC01 was found to have neutralizing activity against both 
HIV-1 strains. However, its activity was found to be several folds lower than the full length 
VRC01 IgG (Fig. 3B). Ten µg/ml of VRC01 was able to achieve 50% neutralization of 
1084i but 50 ug/ml of sc-Fv-VRC01 was needed to achieve similar levels of neutralization 
(see Fig. 3A). This was not unexpected since a single-chain antibody is generally known to 
be weaker than the full-length antibody in binding activity.
Surface display of the scFv-VRC01 antibody on E. coli
In order to display the scFv-VRC01 on the bacterial surface, an anchor protein domain (β-
barrel domain) of IgAP from the autotransporter was added. The IgAP β-barrel domain can 
be integrated into the outer membrane of the bacterial cell wall and will translocate the N-
terminal domain scFv-VRC01 from the cytoplasm to the cell surface. We then generated a 
construct (Fig. 1A and 1B) that included the signal peptide (sp), the single-chain antibody 
(scFv-VRC01), the anchor domain (C-IgAP) and the E-tag for the detection. The induced 
bacterial lysate was tested for the expression of the recombinant fusion protein by western 
blot analysis, and as expected a 75 kDa fusion protein was detected by anti-E-tag antibody 
(Fig. 2E). To verify that this fusion protein molecule could be displayed on the surface of 
the bacterium, flow cytometry was carried out to identify the presence of the recombinant 
scFv-VRC01 using FITC-conjugated rabbit anti-human IgG antibody. Over 50% of the 
bacteria were shown to express scFv-VRC01 on the cell surface (Fig. 4A).
To further confirm the expression of the surface scFV-VRC01 confocal microscopy was 
carried out to directly visualize the presence of the molecule on the bacterial surface using 
FITC labelled antibodies. More than half of the cells were found to be positive (Fig. 4B). 
The results corresponded well with the number of positive cells determined by flow 
cytometry analysis (Fig. 4A), and suggest that the scFv-VRC01 molecules can be displayed 
on the bacterial surface.
Binding and inhibition of HIV-1 infection by the bacterial displayed scFv-VRC01
Since scFv-VRC01 could be expressed in a large number of bacteria, it was important to 
determine whether they could bind to HIV-1 and prevent its infection. To demonstrate that 
the bacteria which displayed surface scFv-VRC01 could adsorb viral particles, they were 
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mixed with viral particles (100µl of 108/ml bacteria, and 12,500 RT units of HIV-1) and the 
amount of unbound viral particles were determined by measuring the residual RT (reverse 
transcriptase) activities in the supernatant after binding. As shown in Fig. 5A, the presence 
of bacteria expressing surface scFv-VRC01 could reduce the RT activity in the supernatant 
by over 90% as compared to 60% non-specific adsorption of the virion by control bacteria. 
The adsorption was specific for HIV-1 since similar levels of inhibition were not observed 
with MuLV control. As expected the scFv-VRC01 bacteria were found to be equally 
effective against multiple strains of HIV-1 (Fig. 5A).
To further confirm the effectiveness of the displayed scFc-VRC01 bacteria in inhibiting 
HIV-1 infection, infectivity assays using CF2-Th cells were carried out. Following 
incubation of the virus with the bacteria, the residual virus in the supernatant was used to 
infect CF2-Th and the infectivity was determined by measuring luciferase activity in the 
target cells. These results support the adsorption data demonstrating that HIV-1 infectivity 
was reduced by over 90% after incubation with the scFc-VRC01 bacteria, while much lower 
levels of inhibition were observed with the control bacteria (Fig. 5B). Thus, the bacterial 
cells with surface displayed scFv-VRC01 have the ability to block HIV-1 infection in vitro.
Discussion
Using commensal bacteria as anti-HIV infection agents is a novel initiative, and 
investigation in this area is still lacking with only very few relevant published reports. In this 
report, we have demonstrated as a proof of principle that the use of the p-domain of an 
autotransporter is able to translocate a single-chain anti-HIV antibody molecule from the 
cytoplasm to efficiently display it on the cell surface. The displayed molecule retained its 
anti-HIV activities and was able to bind to different subtypes of HIV-1, however, our 
expression system still needs to be optimized. Flow cytometry analyses data showed that 
only about 53% of bacterial cells positively displayed the scVRC01 on the cell surface. This 
suggests that either some bacteria are either not expressing the recombinant protein or their 
expression levels were below the detection limit. Another possibility is that some of the 
bacteria might have lost the plasmid upon passaging and propagation, or over expression of 
the recombinant molecule could affect the bacterial viability, and only certain bacteria with 
lower levels of expression had survived. These issues will need to be further investigated 
since stable expression and appropriate display are important factors contributing to the 
success of this approach.
Another issue we encountered is the weaker neutralizing activities by the single chain 
antibody compared to a full length antibody, also indicated in a recent research paper that 
included evalutions of several single-chain antibodies against HIV infection including the 
scFv-VRC01 (West et al., 2012). This phenomenon is actually well documented, single-
chain antibody has weaker binding affinity, and will result in weaker neutralizing activity 
when compared to the native antibody molecule. As we know that the Fab fragment 
antibody has a better affinity than the single-chain antibody for binding to its antigen. 
Therefore, it will be significant for us to display the Fab fragment of the VRC01 antibody to 
increase the neutralizing activity and improve this strategy for application.
Wang et al. Page 5
Virology. Author manuscript; available in PMC 2016 January 15.
N
IH
-P
A
 A
uthor M
anuscript
N
IH
-P
A
 A
uthor M
anuscript
N
IH
-P
A
 A
uthor M
anuscript
Nevertheless, our in vitro study here has shown that the use of bacteria expressing anti-HIV 
inhibitors has the potential to be an alternate approach for the prevention of HIV-1 infection. 
Following this study and after the optimization of expression binding of the antibody 
molecule, it will be necessary to deliver these engineered bacteria into mice for colonization 
studies, examining how long the bacteria can stay viable in the animals and how well the 
bacteria are able to disseminate to different tissue sites. Further, it will be necessary to test 
our system in an animal model, such as a humanized mouse or the SHIV macaque model, 
for viral challenge experiments. This will demonstrate the role and the efficacy of the 
engineered bacteria in preventing HIV-1 infection in vivo before testing any human trials.
Conclusions
This is the first report of using gram-negative commensal bacteria for surface display of 
anti-HIV single-chain antibody to prevent HIV-1 infection. We have successfully displayed 
the anti-HIV-1 single-chain antibody VRC01 on the surface of E. coli bacteria and the 
engineered bacteria have shown neutralizing activity in vitro. It is likely that this approach 
could be expanded to be used in vivo as an alternative approach to prevent HIV-1 
transmission and infection.
Materials and methods
Bacterial strains and vectors
Escherichia coli K-12 strain DH5α, Escherichia coli BL21 (λDE3) (Novagen) E. coli K12 
strain UT5600 (ΔompT) were used for surface display (Lum and Morona, 2012; Maurer et 
al., 1997). pET22b, pET28b (Invitrogen) and PUC57 (GenScript) were used for cloning.
Design of the single-chain antibody and fusion protein
The single-chain antibody VRC01 gene was designed using a linker sequence 
(GGGGSGGGGSGGGGS) to connect the two domains of antibody light chain (VH), and an 
E-tag fragment was added to the N-terminus of the recombinant molecule to be used for 
detection of protein expression. A 789-bp fragment with BamH1 and Xho1 restriction sites 
was synthesized by GenScript (Piscataway, NJ).
The 410 amino acids of the β-barrel domain (C-IgAP) fragment were synthesized from the 
Neisseria gonorrhoeae IgA1 protease gene of C-terminal region from position 3364 to the 
end of the gene at position 4599. An E-tag was added to the N-terminus, and a His-tag was 
added to the end of the β-domain segment. The entire 1302 bp fragment was synthesized by 
GenScript.
The entire fusion protein consists of the signal peptide (sp), scFV-VRC01, the β-domain (C-
IgAP) plus the tags and linkers, which total ~2100 bp and encodes a peptide of ~700 amino 
acids. The structure of the recombinant gene and the predicted 3D structure of the fusion 
protein are shown in Fig. 1A and 1B respectively.
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Expression and purification of scFv-VRC01
The synthesized scFv-VRC01 gene fragment was removed from the original vector pUC57 
using the restriction enzymes BamH1 and Xhol, and then ligated into an E. coli expression 
vector pET28b (Invitrogen). The vector containing scFv-VRC01 gene was transformed into 
E. coli BL21 (ADE3) bacterial cells for protein expression. After transformation, the 
selected positive colonies were cultured and induced by 0.5mM IPTG (isopropylthio-p-
galactoside) for 3 hrs at 37°C. After induction, the cells were collected by centrifugation and 
then disrupted by sonication. To purify the protein from inclusion bodies, the precipitates 
were dissolved in 8M urea and purified by Ni-NTA affinity chromatography under 
denaturing conditions. The protein was dialyzed for 24 hrs at 4°C in refolding buffer 
containing 50mM Tris-HCL, 0.5M L-Arginine, 50mM NaCl and 10% glycerol. The protein 
concentration of purified scFv-VRC01 protein was measured by BCA protein assay (Pierce) 
and stored at −80°C.
Surface expression of scFv-VRC01
The E. coli K-12 strain UT5600 was used as host cells for surface display of the fusion 
protein. The designed β-domain(C-IgAP) gene (1302bp) was synthesized and cloned into the 
pUC57 vector (GenScript). To construct the recombinant expression vector pET22b–scFv-
VRC01-β-domain(C-IgAP), the β-domain-E-tag encoding fragment was cloned into the 
pET22b–scFv-VRC01 vector at the Xhol site to generate the vector pET22b–scFv-VRC01-
β-domain which harbors the main fusion structure of scFv-VRC01, the transporter C-
terminal β-domain of IgAP and the E-tag connecting the two fragments. Transformation of 
E. coli K-12 strain UT5600 was performed as previously described (Lum and Morona, 2012; 
Maurer et al., 1997). For induction of the fusion protein, single colonies were picked and 
inoculated into liquid LB containing 2% (w/v) glucose and antibiotics, and grown at 30°C 
until OD600 was ~0.5. Bacterial cells were then harvested by centrifugation, resuspended 
into similar volume of fresh liquid medium with antibiotics and 0.25mM or 0.5mM IPTG, 
and incubated further at 30°C for 3 hrs.
To verify the expression of the scFv and β-domain of IgAP fusion protein, 0.25mM or 
0.5mM IPTG-induced E. coli cells containing the vectors pET22b–scFv-VRC01-β-domain 
or control empty vector pET22b were centrifuged and resuspended in 20mM phosphate 
buffer. The bacterial suspensions were mixed with 2×SDS sample buffer. After 5 min of 
boiling, samples were briefly centrifuged and subjected to Western blot analysis. To verify 
that the fusion protein was expressed in the insoluble fraction including membranes and 
inclusion bodies, the bacterial cells, both before and after IPTG-induction, were resuspended 
in PBS and sonicated at 15W for 30 seconds 5 times to break open the cells. After sonication 
the samples were spun at 10,000×g for 20 minutes to pellet any unbroken cells or large 
cellular debris. The supernatant was then centrifuged at 100,000×g for 1 hr at 4°C to pellet 
the membrane, and then subjected to Western blot analysis.
SDS-PAGE, Western blotting and Far-Western blotting
Samples were run on a 10% SDS-polyacrylamide gel and stained with Coomassie blue to 
verify protein expression.
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For Western blotting analysis, the SDS-PAGE gel was further transferred to a 
polyvinylidene fluoride (PVDF) membrane (Millipore, USA) and the membrane was 
blocked with blocking buffer (5% skim milk in TBS) for 1 hr at room temperature and 
reacted with primary antibody (5000-fold diluted anti-His-tag antibody HRP conjugated or 
500-fold diluted rabbit anti-E-tag antibody) in blocking buffer for 16 hr at 4°C. The 
membrane was washed 3 times with wash buffer (0.05% tween-20 in TBS) and incubated 
with a secondary antibody (HRP conjugated anti-rabbit IgG antibody) for 1 hr at room 
temperature. After washing 3 times, the membrane was developed with TMB membrane 
peroxidase substrate (KPL, USA). The anti-His-tag antibody HRP conjugated (Abcam) or 
rabbit anti-E-tag antibody HRP conjugated (Bioss Inc) was used for detection.
To examine the single-chain VRC01 antibody (scFV-VRC01) in the fusion molecule, far-
Western blotting was performed. BSA was used as a negative control and HIV-1 gp120 was 
used as a positive control. The purified scFv-VRC01 and the fusion protein containing 
scFV-VRC01 were first separated by SDS-PAGE and then transferred to PVDF membrane. 
In order to refold the proteins on the membrane to generate an intact binding site, a 
denaturation step was added. Briefly, immediately after transfer, the blot was incubated in 
2% AC denaturing buffers (100 mM NaCl, 20 mMTris (pH 7.6), 0.5 mM EDTA, 10% 
glycerol, 0.1% Tween-20, 2% skim milk powder and 1 mM DTT) for 16 hrs at 4°C, the 
membrane was then blocked in 5% skim milk and incubated with 1:250 diluted gp120 in 2% 
AC buffer for 16 hrs at 4°C. The membrane was washed 3 times with wash buffer (0.05% 
tween-20 in TBS) and incubated with HRP conjugated anti-gp120 for 1 hr at room 
temperature. After washing 3 times, the membrane was developed with TMB membrane 
peroxidase substrate (KPL, USA).
Flow cytometry analysis
Bacteria were grown in the presence of IPTG as described above until the log phase, 10µl of 
each E. coli culture (106/ml bacteria) containing the vectors pET22b–scFv-VRC01-β-
domain(C-IgAP) or empty vector pET22b were washed three times in PBS by centrifugation 
(10,000g for 15 min) before they were resuspended in 50µl of PBS. A 20-fold diluted rabbit 
anti-E-tag rabbit antibody conjugated with Fluorescein isothiocyanate (FITC) (Bioss Inc) 
was added and the samples were incubated for 1 hr at 4°C. The washing procedure in PBS 
was repeated once and the samples were resuspended in 300µl of PBS. Bacterial flow 
cytometry analysis was carried out with FACSCalibur (Becton Dickinson) as described 
previously (Gunasekera et al., 2000).
Confocal Microscopy
After growth in the presence of IPTG as described above, 10µl of each E. coli culture 
(106/ml bacteria) containing the vectors pET22b–scFv-VRC01-β-domain or empty vector 
pET22b were washed 3 times in PBS, spunned at 10,000g for 15 min before resuspending in 
50µl of PBS. A 20-fold diluted rabbit anti-E-tag antibody conjugated-FITC (Bioss, Inc) was 
added and the samples were incubated for 1 hr at 4°C. The washing procedure in PBS was 
repeated and the samples were resuspended in 50ul of 2% PFA in PBS. Images were 
collected using a Leica TCS-NT/SP confocal microscope (Leica Microsystems, Mannheim, 
Germany). Standard filters were used for FITC. The detector slits for the FITC channel were 
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configured to collect between 500 and 547 nm to minimize overlapping of the green and 
yellow channels. All images were analyzed using the same gain, and organized using the 
Adobe Photoshop (Adobe Systems, San Jose, CA).
Single-chain antibody neutralization assay
Cf2Th cells with CD4 and CCR5 receptors were used to test the sensitivity of the viruses to 
neutralization by scFv-VRC01. 2,500 RT units of luciferase-expressing recombinant viruses 
were incubated with 50µg, 25µg, 5µg, and 0.5µg, and 0.05µg/ml of scFv-VRC01 in DMEM 
for 60 min at 37°C. The virus-antibody mixtures were then transferred to wells containing 
105/well of target Cf2Th cells. After overnight incubation, 0.1ml of fresh medium was 
added to each well, and the cells were cultured for 2 more days. The cells were then lysed 
and assayed for luciferase activity (Tuner 20; Promega). In another independent experiment, 
we compared the neutralizing activity between scFv-VRC01 and the native IgG VRC01 
antibody (20µg, 10µg, 5µg, and 0.5µg/ml) using a subtype C HIV-1 recombinant luciferase-
expressing virus 1084i.
Viral particles absorption assay
To determine the ability of E. coli expressing scFv-VRC01 on the cell surface to bind 
HIV-1, the bacteria (100µl of 108/ml) were mixed with 12,500 RT units of viral stock (YU2, 
1084i, HXBc2, AMLV) and incubated with rocking for 1 hr at 37°C, then spun down to 
remove the bacteria and RT was measured in the supernatant. RT assay performed as 
described previously (Rho et al., 1981).
Bacteria neutralization assay
To determine the HIV neutralizing activity of E. coli expressing scFv-VRC01 on the cell 
surface, the bacteria (100µl of 108/ml) were mixed with 2,500 RT units of viral stock (YU2, 
1084i, HXBc2, AMLV) and incubated with rocking for 1h at 37°C, then spun down to 
remove the bacteria. The supernatant was then transferred to wells containing the target 
Cf2Th cells. The cells were then lysed and assayed for luciferase activity. The luciferase 
activity assay was performed as described previously (Xiang et al., 2002).
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Highlights
Designed single-chain VRC01 antibody was demonstrated to bind HIV-1 envelope 
gp120.
Single-chain VRC01 antibody was successfully displayed on the surface of E. coli.
Engineered bacteria can absorb HIV-1 particles and prevent HIV-1 infection in cell 
culture.
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Fig. 1. 
Construction of fusion protein of single-chain antibody VRC01 and autotransporter β-
domain from N. gornohoeae(A). Schematic representation of the fusion protein construct for 
surface display. Sp, signal peptide; E, E-tag; L, linker (GSG); scFv, single-chain variable 
fragment; p-domain, the c-terminal part of autotransporter serine proteinase gene of N. 
gornohoeae. H, His-tag. (B). Three dimensional (3D) model of the fusion protein for surface 
display and its binding to gp120. The linker is GSG plus the E-tag, β-barrel domain (PDB 
1UYN (van den Berg, 2010)), scFV-VRC01 and gp120 of HIV-1 (PDB 3NGB).
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Fig. 2. 
Expression and purification of the designed single-chain antibody VRC01 in E. coli(A). 
Polyacrylamide gel with Coomassie blue staining. Lane 1, cell pellet total proteins of un-
induced; 2, cell pellet total proteins of induced; 3, supernatant of cell lysate; 4, pellet of cell 
lysate; 5, Urea-solubilized inclusion bodies. (B). Western blot of the same purified protein 
samples from Fig. 2A using anti-His-tag antibody. The specific band (~27kDa) of scFv 
antibody VRC01 is indicated by the arrow in Fig. 2A and 2B. Western blot to verify the 
purified single-chain antibody VRC01. (C). Western blot with anti-His-tag antibody. Lane1, 
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gp120, 2, scFv_VRC01. (D). Far-Western blot first with the binding of bait protein gp120, 
then with the anti-gp120 antibody. Lane 1, BSA; 2, gp120, 3, scFv-VRC01. (E). Western 
blot of scFv-VRC01 and scFv-VRC01-β-domain fusion protein (~75kDa). Both of the 
samples are labeled with as follows: Lane 1, Supernatant of strain containing plasmid scFv-
VRC01; 2, Supernatant of strain containing plasmid scFv-VRC01-β-domain; 3, Cell pellet 
of strain containing plasmid scFv-VRC01; 4, Cell pellet of strain containing plasmid scFv-
VRC01-β-domain.
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Fig. 3. 
Functional analysis of purified single-chain antibody VRC01. (A). Neutralization assay of 
the scFv-VRC-1 against different strains of HIV-1: YU2 (subtype B), 1084i (subtype C). 
(B). Comparison of the scFv VRC01 antibody and corresponding VRC01 IgG antibody.
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Fig. 4. 
Identification of Surface display of fusion protein on E. coli(A). Bacterial sample cells (E. 
coli) were treated with FITC-conjugated anti-rabbit IgG antibody and analyzed by Flow 
cytometer. Orange, unstained bacterial cells as negative control; green, stained bacteria cells 
harboring the vector only; cyan, stained bacteria harboring the scFv-VRC01-β-domain 
plasmid. The total gated positive cell percentage (M1) is shown in the figure. (B). Bacterial 
Cells displaying scFv-VRC01 on the surface using confocal microscopy. The positive 
stained bacterial cells by FITC-conjugated anti-rabbit IgG antibody are shown in green. The 
same image is shown in (a), dark background window (FITC). (b), the bright background 
window (FITC) + (DIC) (differential interference contrast). The size bar showing in the 
picture is 5.0µ in (a) and 10.0µ in (b).
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Fig. 5. 
(A).Adsorption of HIV-1 particles by scFv-VRC01 surface displayed bacteria. The 
engineered bacteria with the concentration of 108/ml mixed with the viral stock can reduce 
the viral titer by surface binding. HIV-1 strains: YU2 (R5 virus, subtype B), 1084i (R5 virus, 
subtype C), HXBc2 (X4 virus, subtype B), AMLV, unrelated virus. RT, reverse 
transcriptase. (B). Inhibition of viral infection by scFv-VRC01 surface displayed bacteria in 
vitro. The target cells (Cf2Th) stably expressed receptor CD4 and co-receptor CCR5 were 
used for infection, and the luciferase was a reporter gene. HIV-1 strains: YU2 (R5 virus, 
subtype B), 1084i (R5 virus, subtype C), HXBc2 (X4 virus, subtype B) as negative control, 
AMLV, unrelated virus.
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